Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer

To study epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance mechanisms, we established a novel gefitinib-resistant lung cancer cell line derived from an EGFR-mutant non-small cell lung cancer cell line (PC-9) pretreated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanon...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Experimental cell research 2014-03, Vol.322 (1), p.168-177
Hauptverfasser:	Ochi, Nobuaki, Takigawa, Nagio, Harada, Daijiro, Yasugi, Masayuki, Ichihara, Eiki, Hotta, Katsuyuki, Tabata, Masahiro, Tanimoto, Mitsune, Kiura, Katsuyuki
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - metabolism Cell Line, Tumor Cellular biology Drug Resistance, Neoplasm - genetics EGFR Enzyme Activation Epidermal growth factor ERK Extracellular Signal-Regulated MAP Kinases - metabolism Gefitinib Humans Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - metabolism Nitrosamines - pharmacology Phosphorylation Phosphorylation - drug effects Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins pp60(c-src) - physiology Quinazolines - pharmacology Quinazolines - therapeutic use Resistance Signal transduction Src
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!